Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCohort Regulatory News (CHRT)

Share Price Information for Cohort (CHRT)

Share Price is delayed by 15 minutes
Get Live Data
1,276.00    20.00 (1.59%)
Bid:
1,270.00
Ask:
1,278.00
Spread: 8.00 (0.63%)
Market Cap: £584.74m
CHRT Live PriceLast checked at - London Stock Exchange

Intraday Cohort Share Chart

Contract Win

25 Jul 2016 07:00

RNS Number : 0496F
Cohort PLC
22 July 2016
 

25 July 2016

 

Cohort plc

("Cohort" or "the Group")

 

Contract Win

MCL awarded Airborne Tactical Communications Support Contract

Cohort, the independent technology group, today announces that its subsidiary Marlborough Communications Ltd (MCL), has been awarded the UK MOD Airborne Tactical Communications Support Contract.

The contract, valued at up to £7.7m, is to provide support to certain specialist equipment and includes options covering additional development activities. The duration of the contract will be between two and six years, with a minimum value of around £0.9m, depending on the options chosen by the customer. MCL will be supported by its partner Serbus Ltd in the delivery of the contract.

Andrew Thomis, Chief Executive of Cohort plc said:

"This is another excellent win for MCL demonstrating its extremely strong capability in this specialist area. After many years successfully delivering land based tactical communications, we are pleased to have built on this experience enabling this, our first win in the tactical airborne environment.

"This adds further visibility to our order book, which underpins a significant proportion of revenues for Cohort's current financial year."

Ends

For further information please contact:

Cohort plc

0118 909 0390

Andy Thomis, Chief Executive

 

Simon Walther, Finance Director

 

Investec Bank plc

020 7597 5970

Keith Anderson / Daniel Adams

 

MHP Communications Limited

020 3128 8100

Reg Hoare / Jamie Ricketts / Ollie Hoare

 

 

NOTES TO EDITORS

Cohort plc (www.cohortplc.com) is the parent company for five innovative, agile and responsive businesses working primarily for defence, wider government and industry clients. 

· EID (www.eid.pt) - a Portugal based supplier of advanced communications products and systems for the global defence market. EID has been part of the Group since June 2016.

 

· MASS (www.mass.co.uk) - a specialist defence and technology business, focused mainly on electronic warfare, information systems and cyber security. Acquired by Cohort in August 2006.

· MCL (www.marlboroughcomms.com) - an expert in sourcing, design and integration of communications and surveillance technology, as well as support and training for UK end users including the MOD and other government agencies. MCL has been part of the Group since July 2014.

 

· SCS (www.scs-ltd.co.uk) - a defence consultancy, combining technical expertise with armed forces experience and domain knowledge. Owned by Cohort since flotation in March 2006. 

 

· SEA (www.sea.co.uk) - an advanced electronic systems and software house operating in the defence, transport and offshore energy markets. Acquired by Cohort in October 2007. 

 

Cohort (AIM: CHRT) was admitted to London's Alternative Investment Market in March 2006. It has its headquarters in Berkshire and employs in total around 800 core staff there and at its other operating company sites in Bristol, Cambridgeshire, Devon, Lincolnshire, Somerset, Surrey, Scotland and Portugal.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTAKBDBABKDDOB
Date   Source Headline
1st Jun 202611:41 amRNSTotal Voting Rights
27th May 20267:00 amRNSFull Year Trading Update
26th May 20267:00 amRNSNotice of Full Year Trading Update
12th May 202610:46 amRNSHolding(s) in Company
1st May 20269:37 amRNSTotal Voting Rights
10th Apr 20263:58 pmRNSDirector/PDMR Shareholding
10th Apr 202612:35 pmRNSHolding(s) in Company
2nd Apr 20267:00 amRNSBlock Listing Six Monthly Return
1st Apr 202610:10 amRNSTotal Voting Rights
26th Mar 20267:00 amRNSContract Announcement
23rd Mar 20267:00 amRNSContract Announcement
2nd Mar 202611:57 amRNSTotal Voting Rights
25th Feb 20269:51 amRNSBlock Listing Six Monthly Return
20th Feb 20267:00 amRNSDirector/PDMR Shareholding
17th Feb 20263:41 pmRNSHolding(s) in Company
16th Feb 20267:00 amRNSDirector/PDMR Shareholding
4th Feb 20269:35 amRNSHolding(s) in Company
2nd Feb 20264:54 pmRNSTotal Voting Rights
30th Jan 20267:00 amRNSContract Wins
20th Jan 202612:40 pmRNSHolding(s) in Company
15th Jan 20267:00 amRNSInterim Report 2025
5th Jan 20269:00 amRNS-RInvestor Presentation via Equity Development
2nd Jan 202612:40 pmRNSTotal Voting Rights
22nd Dec 20259:00 amRNS-RInvestor Presentation via Engage Investor
22nd Dec 20259:00 amRNS-RInvestor Presentation via Engage Investor
15th Dec 202511:56 amRNSDirector/PDMR Shareholding
11th Dec 20257:00 amRNSDirector/PDMR Shareholding
10th Dec 20257:01 amRNSHalf Year Results
1st Dec 202512:20 pmRNSTotal Voting Rights
28th Nov 20257:00 amRNSNotice of Half Year Results
4th Nov 202511:59 amRNSTotal Voting Rights
27th Oct 20254:37 pmRNSDirector/PDMR Shareholding
16th Oct 202510:11 amRNSDirector/PDMR Shareholding
7th Oct 20253:15 pmRNSDirector/PDMR Shareholding
7th Oct 20257:00 amRNSMASS secures £15.7m countermeasures contract
2nd Oct 202511:03 amRNSBlock Listing Six Monthly Return
1st Oct 20259:53 amRNSTotal Voting Rights
25th Sep 20254:59 pmRNSResult of AGM
25th Sep 20257:00 amRNSAGM Statement
19th Sep 20255:12 pmRNSDirector/PDMR Shareholding
12th Sep 20257:00 amRNS-RInvestor Presentation
10th Sep 20253:21 pmRNSDirector/PDMR Shareholding
3rd Sep 202510:57 amRNSDirector/PDMR Shareholding
1st Sep 202511:05 amRNSTotal Voting Rights
26th Aug 20253:22 pmRNSBlock Listing Six Monthly Return
20th Aug 20253:56 pmRNSAnnual Report and Notice of Annual General Meeting
15th Aug 20253:35 pmRNSDirector/PDMR Shareholding
11th Aug 20255:10 pmRNSDirector/PDMR Shareholding
1st Aug 20254:16 pmRNSTotal Voting Rights
17th Jul 20259:49 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.